Lung Transplant RejectionLANDSCAPENCT05655208
Histological Profiles of Lung Allograft Transbronchial Biopsies and Clinical Outcomes After Lung Transplantation
An observational study of Lung Transplant Rejection, run by Paris Translational Research Center for Organ Transplantation.
Trial summary
Lung transplantation is the only curative treatment for individuals with end-stage lung disease. Understanding the lung allograft's histological lesions, which is key for the patient management, remains difficult because of the multiplicity of lesions associated with graft outcome and their interpenetration. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Lung Transplant Rejection
- How many people
- 498 participants
- Where
- No sites listed yet
- Study dates
- 1 Feb 2010to 30 Nov 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This prospective cohort included consecutive lung transplant recipients who were transplanted between February 2010 and November 2019 in Foch Hospital and were eligible for inclusion. Every protocol and for cause transbronchial biopsies (TBBs) identified in the Foch hospital database for each patient were analyzed using standardized template. Reports of TBB with one or more missing values were excluded. Protocol TBB were performed after transplantation with the following scheme : month 1 (M1) at 30 ± 10 days, month 2 (M2): 60 ± 10 days, month 3 (M3): 90 ± 10 days, month 4 (M4): 120 ± 10 days, month 6 (M6): 180 ± 10 days, month 9 (M9): 270 ± 10 days and month 12 (M12): 365 ± 10 days. For cause TBB were performed in case of graft dysfunction.
Who may be able to join
- i) age greater than 18 years,
- ii) single or bilateral lung transplantation,
- iii) having at least one transbronchial biopsy available for analysis
- iv) consent their clinical data to be used for research
Who cannot join
- Biopsies with at least one missing value in the standardized clinical report were excluded
About this study
Lung transplantation is the only curative treatment for individuals with end-stage lung disease. Understanding the lung allograft's histological lesions, which is key for the patient management, remains difficult because of the multiplicity of lesions associated with graft outcome and their interpenetration.
The goal of this observational study is to identify clusters of histological lesion on transbronchial biopsies in Lung transplant recipient prospective cohort.
The main question[s] it aims to answer are:
- what are the different pattern of histological lesion?
- what are the graft outcome associated with the different clusters?
Read the detailed description
SCIENTIFIC JUSTIFICATION:
With more than three million deaths per year, the chronic obstructive pulmonary disease is currently the third cause of mortality worldwide , and contributes to the growing number of individuals with end-stage lung disease, which is now a major issue for world public health. Overall, for individuals with end-stage lung disease, lung transplantation (LTx) is the only treatment able to increase patient survival and quality of life, with more than 4,500 lung transplantations performed each year.
Despite major progresses made in the last decade regarding organ preservation, procurement and short term outcome little improvements have been made on the histological characterization of rejection, which remains the main determinant of patient death after lung transplantation.
One of the main limitation of histological analysis is the multiplicity of lesions associated with graft outcome and their interpenetration. Historically, the perivascular infiltrate or cellular rejection (A lesions), and the lymphocytic bronchiolitis (B lesions) are the first histological lesions associated with graft dysfunction and stand as key parameters in patient management. In addition to A and B lesions, a wide spectrum of histological lesions of the lung allograft is associated with clinical outcomes.
However, to our best knowledge, only few studies thoroughly investigated the various elementary lesions in the broad scope of histological analysis, and their association with clinical outcomes. Although informative, those studies usually suffer from a small number of patients, convenience clinical samples from registry, and the lack of innovative statistical approach. Overall, the wide spectrum of the allograft lesions has not been investigated using a large number of transbronchial biopsies with standardized protocol and biopsy reading, and a multidimensional approach on deeply phenotyped data.
The recent use of unsupervised method in organ transplantation has permitted the identification of clinically relevant patient clusters and may be a relevant strategy to decipher the heterogeneity in histological lesions in lung recipients.
Therefore, using a deeply phenotyped prospective cohort of lung recipients and consecutive transbronchial biopsies with protocolized evaluation and interpretation covering the different cases scenario encountered in clinical practice, the investigators aim to identify histological clusters based on histological lesions and assess their associations with graft and patient outcomes.
OBJECTIVES:
Main objective: To identify of histological cluster of lung allograft Transbronchial biopsies
Secondary objective: To evaluate association of each cluster with baseline clinical data and anti HLA donor specific antibody and graft outcome
INTERVENTIONS:
This is an observational study that involves only minimal risk and constraints. The intervention consists in the evaluation of parameters measured as part of the standard of care at the time of post-transplant allograft biopsy.
No medicinal product is under investigation in this protocol.
EXPECTED BENEFITS for the participants and for society:
There will be no immediate individual benefit for the patient to participate in the study.
This study will provide us with data of Lung transplant patients that may allow the improvement of clinical decisions and the long-term lung allograft management.
MINIMAL RISKS AND CONSTRAINTS added by the study No additional intervention beyond the standard of care will be performed in this study.
RECRUITING CENTER:
- Single center study
- Hopital Foch, Suresnes, France
- Conditions
- Lung Transplant Rejection
- Keywords
- Lung transplantation, Rejection, Transbronchial biopsy, Donor specific Antibody, Cluster analysis
- Medical subject headings
- Rejection, Psychology
What is being measured
The primary outcome is the main question the study is designed to answer.
graft loss resulting in death or re-transplantation and all-cause mortality
Measured: 118 months
Secondary outcomes (1)
chronic lung allograft dysfunction occurrence
Measured: 118 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Dec 2022
- Study start1 Feb 2010
- Primary completion30 Nov 2019
- Study completion30 Nov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Transplant RejectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 498 participants (actual)
Sponsor and investigators
- Lead sponsor
- Paris Translational Research Center for Organ Transplantation
- Sponsor type
- University, hospital or other
- Collaborators
- Hopital Foch
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05655208
- Sponsor's protocol ID
- LungCluster
- Acronym
- LANDSCAPE
- Status last verified
- Mar 2023
- First submitted
- 29 Nov 2022
- Last updated
- 29 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: We will agree to share IPD under reasonnable request and for research purpose only. Any request should be send to Pr Roux Antoine at the following email adress: rouxantoine@hotmail.com
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Histological Profiles of Lung Allograft Transbronchial Biopsies and Clinical Outcomes After Lung Transplantation
- ClinicalTrials.gov ID
- NCT05655208
- Acronym / sponsor ID
- LANDSCAPE / LungCluster
- Conditions
- Lung Transplant Rejection
- Keywords
- Lung transplantation, Rejection, Transbronchial biopsy, Donor specific Antibody, Cluster analysis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 498 participants (actual)
- Lead sponsor
- Paris Translational Research Center for Organ TransplantationUniversity, hospital or other
- Collaborators
- Hopital Foch
- Study start
- 1 Feb 2010 (actual)
- Primary completion
- 30 Nov 2019 (actual)
- Study completion
- 30 Nov 2019 (actual)
- First posted
- 19 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung transplantation is the only curative treatment for individuals with end-stage lung disease. Understanding the lung allograft's histological lesions, which is key for the patient management, remains difficult because of the multiplicity of lesions associated with graft outcome and their interpenetration.
The goal of this observational study is to identify clusters of histological lesion on transbronchial biopsies in Lung transplant recipient prospective cohort.
The main question[s] it aims to answer are:
- what are the different pattern of histological lesion?
- what are the graft outcome associated with the different clusters?
Detailed description
SCIENTIFIC JUSTIFICATION:
With more than three million deaths per year, the chronic obstructive pulmonary disease is currently the third cause of mortality worldwide , and contributes to the growing number of individuals with end-stage lung disease, which is now a major issue for world public health. Overall, for individuals with end-stage lung disease, lung transplantation (LTx) is the only treatment able to increase patient survival and quality of life, with more than 4,500 lung transplantations performed each year.
Despite major progresses made in the last decade regarding organ preservation, procurement and short term outcome little improvements have been made on the histological characterization of rejection, which remains the main determinant of patient death after lung transplantation.
One of the main limitation of histological analysis is the multiplicity of lesions associated with graft outcome and their interpenetration. Historically, the perivascular infiltrate or cellular rejection (A lesions), and the lymphocytic bronchiolitis (B lesions) are the first histological lesions associated with graft dysfunction and stand as key parameters in patient management. In addition to A and B lesions, a wide spectrum of histological lesions of the lung allograft is associated with clinical outcomes.
However, to our best knowledge, only few studies thoroughly investigated the various elementary lesions in the broad scope of histological analysis, and their association with clinical outcomes. Although informative, those studies usually suffer from a small number of patients, convenience clinical samples from registry, and the lack of innovative statistical approach. Overall, the wide spectrum of the allograft lesions has not been investigated using a large number of transbronchial biopsies with standardized protocol and biopsy reading, and a multidimensional approach on deeply phenotyped data.
The recent use of unsupervised method in organ transplantation has permitted the identification of clinically relevant patient clusters and may be a relevant strategy to decipher the heterogeneity in histological lesions in lung recipients.
Therefore, using a deeply phenotyped prospective cohort of lung recipients and consecutive transbronchial biopsies with protocolized evaluation and interpretation covering the different cases scenario encountered in clinical practice, the investigators aim to identify histological clusters based on histological lesions and assess their associations with graft and patient outcomes.
OBJECTIVES:
Main objective: To identify of histological cluster of lung allograft Transbronchial biopsies
Secondary objective: To evaluate association of each cluster with baseline clinical data and anti HLA donor specific antibody and graft outcome
INTERVENTIONS:
This is an observational study that involves only minimal risk and constraints. The intervention consists in the evaluation of parameters measured as part of the standard of care at the time of post-transplant allograft biopsy.
No medicinal product is under investigation in this protocol.
EXPECTED BENEFITS for the participants and for society:
There will be no immediate individual benefit for the patient to participate in the study.
This study will provide us with data of Lung transplant patients that may allow the improvement of clinical decisions and the long-term lung allograft management.
MINIMAL RISKS AND CONSTRAINTS added by the study No additional intervention beyond the standard of care will be performed in this study.
RECRUITING CENTER:
- Single center study
- Hopital Foch, Suresnes, France
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This prospective cohort included consecutive lung transplant recipients who were transplanted between February 2010 and November 2019 in Foch Hospital and were eligible for inclusion. Every protocol and for cause transbronchial biopsies (TBBs) identified in the Foch hospital database for each patient were analyzed using standardized template. Reports of TBB with one or more missing values were excluded. Protocol TBB were performed after transplantation with the following scheme : month 1 (M1) at 30 ± 10 days, month 2 (M2): 60 ± 10 days, month 3 (M3): 90 ± 10 days, month 4 (M4): 120 ± 10 days, month 6 (M6): 180 ± 10 days, month 9 (M9): 270 ± 10 days and month 12 (M12): 365 ± 10 days. For cause TBB were performed in case of graft dysfunction.
Key inclusion criteria (4 listed)
- i) age greater than 18 years,
- ii) single or bilateral lung transplantation,
- iii) having at least one transbronchial biopsy available for analysis
- iv) consent their clinical data to be used for research
Key exclusion criteria (1 listed)
- Biopsies with at least one missing value in the standardized clinical report were excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
graft loss resulting in death or re-transplantation and all-cause mortality
Time frame: 118 months
1 secondary outcome
chronic lung allograft dysfunction occurrence
Time frame: 118 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2023.
- Individual participant dataSharing planned: Yes. We will agree to share IPD under reasonnable request and for research purpose only. Any request should be send to Pr Roux Antoine at the following email adress: rouxantoine@hotmail.com
Related trials for Lung Transplant Rejection
RecruitingPhase 1
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
Lung Transplantation
RecruitingPhase 3
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
Lung Transplant Rejection
RecruitingPhase 1
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
Antibody Mediated Rejection of Lung Transplant
RecruitingPhase 2
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Lung Transplant
RecruitingObservational study
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
Lung Transplant; Complications, Lung Transplant; Infection or Inflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Transplant Rejection, run by Paris Translational Research Center for Organ Transplantation.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
graft loss resulting in death or re-transplantation and all-cause mortality (time frame: 118 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2023.